- Trial phase
- Approved
- Time to market
- Already approved and commercially available in the US (since 2022), EU (Immedica became MAH in June 2025), and China (approved 2024). No new approval decision is pending.
- Why 3/10
- No hard dated binary catalyst exists for ganaxolone in the next ~12 months from LGND's perspective. The drug is already approved and commercialized. Immedica's planned new Phase 3 study for IV ganaxolone (announced Oct 2026) targets a 2027 start, more than 12 months away, and Ligand's exposure is through Captisol supply, which is a very small component (Captisol revenue ~$8.7M total) of its diversified >200-asset portfolio.
No near-term binary catalyst exists for ganaxolone affecting LGND. Immedica (private) plans to launch a new Phase 3 study of IV ganaxolone in refractory status epilepticus in 2027, but this is several years from any commercial outcome and Ligand's Captisol exposure is small. Watch Immedica's commercial execution for Ztalmy and any label expansions, but none are likely to move LGND stock materially.
Price Chart
Executive Summary
Ganaxolone (brand name Ztalmy) is an FDA-approved neuroactive steroid for seizures in CDKL5 deficiency disorder (CDD), approved in March 2022. It was developed by Marinus Pharmaceuticals (MRNS), which was acquired by private Swedish rare-disease firm Immedica Pharma in February 2025 for $151M. The filing-hint ticker LGND (Ligand Pharmaceuticals) holds a Captisol formulation license and supply agreement for Captisol-enabled ganaxolone, but this is a minor revenue source within Ligand's diversified portfolio of over 200 royalty assets (total Captisol revenue ~$8.7M in 2026). Ganaxolone has no pending binary catalyst for LGND and represents a very small slice of Ligand's value.
How It Works
Ganaxolone is a synthetic version of a natural brain steroid. It works by boosting the activity of GABA, the brain's main calming/ inhibitory chemical signal. This reduces over-excitation that causes seizures. It is taken as an oral liquid suspension.
Trial Status
Ganaxolone was approved by the FDA in March 2022 for CDKL5 deficiency disorder (CDD) based on the positive Phase 3 Marigold trial. Two subsequent Phase 3 trials in other indications failed: the TrustTSC trial in tuberous sclerosis complex did not meet its primary endpoint (p=0.09, Oct 2024), and the RAISE trial in refractory status epilepticus met only one of two co-primary endpoints (June 2024). Immedica (the current owner) announced on Oct 26, 2026 it plans a new Phase 3 study of IV ganaxolone in refractory status epilepticus, to start in 2027.
The Two-Sided Case
Upcoming Catalysts
- Immedica plans to initiate a new Phase 3 study of IV ganaxolone in refractory status epilepticus in 2027 (distant, not a near-term catalyst for LGND)
- Continued commercial uptake of Ztalmy in CDD indication globally
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Ligand Pharmaceuticals PRESS-RELEASE LGND ·Originating report